RESEARCH PAPER
Effect of demographic factors on brachytherapy treatment results in patients with endometrial cancer 1995–2010
 
More details
Hide details
1
Department of Mother and Child Health, Poznan University of Medical Sciences, Poland
2
Clinic of Surgical Gynaecology, Poznan University of Medical Sciences, Poland
 
Ann Agric Environ Med. 2013;20(4):849–853
KEYWORDS
ABSTRACT
Introduction:
Approximately 1 in 20 female cancers in Europe is of the endometrium. Endometrial carcinoma is the most common gynaecologic cancer. Considering the fact that an upward tendency has recently been observed in morbidity due to this type of cancer, this is a serious medical problem.

Objective:
The presented report describes the results of the analysis of selected demographic factors and their effect on the incidence of endometrial cancer. Analysis of the results of treatment of endometrial cancer during 1995–2010 was also an objective of the study.

Material and Methods:
Based on medical records obtained from the HDR Laboratory of Brachytherapy at the Gynaecological & Obstetrics Clinical Hospital, University of Medical Sciences in Poznań, the results of treatment of patients with endometrial cancer by brachytherapy were analyzed. The analysis covered a group of 400 patients.

Results:
More than a half of the patients completed their education on the level of elementary or secondary school. Taking into consideration the weight of the patients, it appeared that most women had excessive body weight. Most frequently, concomitant hypertension was observed. Moreover, the age at menarche was 12 and 13.

 
REFERENCES (23)
1.
Sobczuk A, Wrona M, Sobotkowski J, Szymczak W, Pertyński T. Otyłość, cukrzyca, nadciśnienie tętnicze a ryzyko raka błony śluzowej trzonu macicy. Przegl Menopauz. 2007; 5: 289–297.
 
2.
Bidziński M, Dańska-Bidzińska A, Derlatka P, Sobiczewski P, Gmyrek L, et al. Recurrence risk analysis in patients treated for I clinical stage of endometrial cancer. Ginekol Pol. 2007; 78: 471–475.
 
3.
Dobrzycka B, Terlikowski S, Kwiatkowski M, Garbowicz M, Kinalski M, et al. Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer Ginekol Pol. 2010; 81: 422–425.
 
4.
Mrozikiewicz P, Grześkowiak E, Seremak-Mrozikiewicz A, Bogacz A, Barlik M, et al. Importance of CYP1A1 polymorphism and its transcriptional regulation in ovarian and endometrial cancer. Ginekol Pol. 2011; 82(12): 925–932.
 
5.
Gottwald L, Chałubińska J, Moszyńska-Zielińska M, Piekarski J, Tyliński W, et al. Endometrioid endometrial cancer – the prognostic value of selected clinical and pathological parameters. Ginekol Pol 2011; 82(10): 743–748.
 
6.
Levi F, La Vecchia CL, Decarli A. Cigarette smoking and the risk endometrial cancer. Eur J Cancer Clin Oncol. 1987; 23: 1025–1029.
 
7.
Wynder E, Escher G.C, Mantel N. An Epidemiological investigations of cancer of the endometrium. Cancer. 1966; 19: 489–520.
 
8.
Rosenberg L, Shapiro S, Kaufman DW. Patterns and determinants of conjugated estrogen use. Am J Epidemiol. 1979; 109: 676–686.
 
9.
Kelsey JI, Lavolsi VA, Holford T. A case control-study of cancer of the endometrium. Am J Epidemiol. 1982; 116: 33–341.
 
10.
Schottenfeld D, Berg J. Incidence of multiple primary cancers. IV. Cancers of the female breast and genitalial organs. J Natl Cancer Inst. 1971; 46: 161–170.
 
11.
Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol. 1993; 81: 265–271.
 
12.
Weiderpass E, Persson I, Adami HO, et al. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer. Cancer Causes Control. 2000; 11(2): 185–192.
 
13.
Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer. 2003; 104(6): 669–76.
 
14.
Yang TY, Cairns BJ, Allen N, Sweetland S, Reeves GK, et.al. Postmenopausal endometrial cancer risk and body size in early life and middle age: prospective cohort study. Br J Cancer. 2012; 107(1): 169–75.
 
15.
Vasena HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on Hereditary non-polyposis colorectal cancer (ICG-HNPCC) Dis. Colon Rectum 1991; 34: 424–425.
 
16.
Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009; 16(1): 14–22.
 
17.
Garcia-Domenech RV, Inesta JM, Asius E, et.al. Prognostic factors in endometrial carcinoma: risk groups and adjuvant radiotherapy. Eur J Gynaecol Oncol. 1997; XVIII: 164–170.
 
18.
Friedenreich CM, Langley A, Speidel TP, Lau DC, Courneya KS, et.al. Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr Relat Cancer. 2012 Oct 2. [Epub ahead of print].
 
19.
Elwood JM, Cole P, Rothamn KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst. 1977; 59: 1055–1060.
 
20.
La Vecchia C, Franceschi S, Decardi A. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst. 1984; 73: 667–671.
 
21.
Parslov M, Lidegaard O, Klintrop S, et al. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynaecol. 2000; 182: 23–29.
 
22.
Olejek A, Olszak-Wąsik K, Horzelski T, Nowak L, Zamłyński J, et al. Rak błony śluzowej macicy u 25-letniej pacjentki. Opis przypadku. Ginekol Pol. 2012; 83: 224–228.
 
23.
Grosman-Dziewiszek P, Dziegiel P, Zabel M. Disturbance of gene expression in endometrial cancer as therapy aim. Ginekol Pol. 2011; 82: 276–280.
 
eISSN:1898-2263
ISSN:1232-1966